In clinical trials, PD-L1 tumor expression is considered a poor predictor of objective response to checkpoint inhibition, where patients benefit from the treatment independently of PD-L1 expression levels detected in tumor samples [12,23,32]. Here, CD274 is linked to neoplasm.